Viktor Umansky
Overview
Explore the profile of Viktor Umansky including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
149
Citations
8509
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Ozbay Kurt F, Cicortas B, Balzasch B, de la Torre C, Ast V, Tavukcuoglu E, et al.
J Immunother Cancer
. 2024 Sep;
12(9).
PMID: 39266214
Background: Immunotherapies for malignant melanoma are challenged by the resistance developed in a significant proportion of patients. Myeloid-derived suppressor cells (MDSC), with their ability to inhibit antitumor T-cell responses, are...
2.
Hering M, Madi A, Sandhoff R, Ma S, Wu J, Mieg A, et al.
Nat Commun
. 2024 Jul;
15(1):6067.
PMID: 39025856
After recognizing its ligand lipopolysaccharide, Toll-like receptor 4 (TLR4) recruits adaptor proteins to the cell membrane, thereby initiating downstream signaling and triggering inflammation. Whether this recruitment of adaptor proteins is...
3.
Lasser S, Ozbay Kurt F, Fritz L, Gutzeit N, de la Torre C, Altevogt P, et al.
Int J Mol Sci
. 2024 Jun;
25(12).
PMID: 38928399
The ability of tumor-derived extracellular vesicles (EVs) to modulate the function of myeloid cells is widely recognized. Hence, a comprehensive understanding of the distinct components associated with EVs and the...
4.
Moller M, Orth V, Umansky V, Hetjens S, Braun V, Reissfelder C, et al.
Front Immunol
. 2024 Jun;
15:1403771.
PMID: 38855104
Background: Immunotherapeutic approaches, including immune checkpoint inhibitor (ICI) therapy, are increasingly recognized for their potential. Despite notable successes, patient responses to these treatments vary significantly. The absence of reliable predictive...
5.
Lasser S, Ozbay Kurt F, Arkhypov I, Utikal J, Umansky V
Nat Rev Clin Oncol
. 2024 Jan;
21(2):147-164.
PMID: 38191922
Anticancer agents continue to dominate the list of newly approved drugs, approximately half of which are immunotherapies. This trend illustrates the considerable promise of cancer treatments that modulate the immune...
6.
Lepper A, Bitsch R, Ozbay Kurt F, Arkhypov I, Lasser S, Utikal J, et al.
Oncoimmunology
. 2023 Aug;
12(1):2247303.
PMID: 37593676
Treatment with immune checkpoint inhibitors (ICIs) has improved the prognosis of melanoma patients. However, ICIs can cause an overactivation of the immune system followed by diverse immunological side effects known...
7.
Ozbay Kurt F, Lasser S, Arkhypov I, Utikal J, Umansky V
J Clin Invest
. 2023 Jul;
133(13).
PMID: 37395271
Despite the remarkable success of immune checkpoint inhibitors (ICIs) in melanoma treatment, resistance to them remains a substantial clinical challenge. Myeloid-derived suppressor cells (MDSCs) represent a heterogeneous population of myeloid...
8.
Steinfass T, Poelchen J, Sun Q, Mastrogiulio G, Novak D, Vierthaler M, et al.
Exp Hematol Oncol
. 2023 Mar;
12(1):29.
PMID: 36906639
Melanoma is the deadliest form of skin cancer showing rising incidence over the past years. New insights into the mechanisms of melanoma progression contributed to the development of novel treatment...
9.
Petrova V, Groth C, Bitsch R, Arkhypov I, Simon S, Hetjens S, et al.
Front Immunol
. 2023 Mar;
14:1065767.
PMID: 36860876
Purpose: Although the treatment of advanced melanoma patients with immune checkpoint inhibitors (ICI) significantly increased the therapeutic efficiency, many patients remain resistant to ICI that could be due to immunosuppression...
10.
Ozbay Kurt F, Lepper A, Gerhards C, Roemer M, Lasser S, Arkhypov I, et al.
Front Immunol
. 2022 Oct;
13:1012526.
PMID: 36311732
A gradual decay in humoral and cellular immune responses over time upon SAR1S-CoV-2 vaccination may cause a lack of protective immunity. We conducted a longitudinal analysis of antibodies, T cells,...